Mesenchymal stromal cell (MSC) therapy represents a growing therapeutic and commercial
value proposition, owing to their paracrine effects, immmunomodulatory properties,
and regenerative potential. Developing bioassays of MSC potency that inform biological
traits relevant for therapeutic strategy are critical. Further, a shift from planar
(culture flasks) to scalar technologies (controlled bioreactors) is increasingly appreciated
to ensure functional consistency between product lots, in addition to better process
control. Yet, existing methods for stem cell quality-control are resource-intensive
and suffer poor alignment with scalar bioprocesses, as they fail to provide for a
quick, real time, in-process potency measurement. To this end, we have developed a
fluorescent probe for detecting potent/proliferative MSCs, and yet another probe for
detecting senescent MSCs, which allow for in-process analysis of stem cell potency
and senescence. High-throughput screening of in-house, cell-permeable, auto-fluorescent
compound library was performed using proliferative, potent human MSC population, and
functionally inferior, senescent MSCs. Potency of MSC populations was qualified by
studying their characteristic surface marker profiles, tri-lineage differentiation
potential, secretome analysis and tubulation assays. MSC senescence was qualified
by assessing growth kinetics, cell-cycle & CFU-F analysis, β-galactosidase staining,
and senescence associated secretory phenotype. Through such screening, we have established
live, fluorescent probes for specific detection of both proliferative, potent MSCs,
and senescent, less-potent human MSCs. These probes have also been validated using
human MSCs from various sources such as bone-marrow, adipose tissue and umbilical
cord. Merits of our strategy are in a specific, reproducible, potency measure that
informs product attributes, following ISCT's minimal criteria, and which can be extended
to include adequate controls for assay validation. Hence these probes could help inform
bioprocess optimization strategies for developing potent stem cell products, and potentially
aid in the identification of high-quality stem-cell sources, and/or donors.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect